Revolution Medicines Inc (RVMD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $37.27B
Last updated: Nov 17, 2026 at 11:06 AM ET
Revolution Medicines Inc (RVMD) Earnings: Report Dates and Results
Revolution Medicines (RVMD) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Revolution Medicines reported EPS of -$1.90, above the -$2.34 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RVMD has an expected report date of Feb 23, 2027.
RVMD Earnings Call
The latest RVMD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 27 quarters below that had an estimate, RVMD beat 6 and missed 21. The widest gap in the table came in the quarter ended Mar 31, 2020, when EPS landed 105.56% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.90 | -$2.34 | -$3.24 - -$2.07 | +18.80% | Beat | N/A | 21 | 3 up, 3 down | Nov 4, 2026 | $197.56M |
| Jun 30, 2026 | -$2.34 | -$1.93 | -$2.34 - -$1.89 | -21.24% | Miss | N/A | 16 | 0 up, 3 down | Aug 5, 2026 | N/A |
| Mar 31, 2026 | -$2.29 | -$1.84 | -$1.96 - -$1.61 | -24.46% | Miss | N/A | 15 | N/A | May 6, 2026 | N/A |
| Dec 31, 2025 | -$1.86 | -$1.58 | -$1.70 - -$1.15 | -17.72% | Miss | N/A | 15 | 1 up, 0 down | Feb 25, 2026 | N/A |
| Sep 30, 2025 | -$1.61 | -$1.39 | -$1.58 - -$1.15 | -15.83% | Miss | N/A | 16 | 0 up, 1 down | Nov 5, 2025 | N/A |
| Jun 30, 2025 | -$1.31 | -$1.12 | -$1.18 - -$1.02 | -16.96% | Miss | N/A | 8 | 0 up, 1 down | Aug 6, 2025 | N/A |
| Mar 31, 2025 | -$1.13 | -$1.06 | -$1.16 - -$0.89 | -6.60% | Miss | N/A | 8 | 0 up, 2 down | May 7, 2025 | N/A |
| Dec 31, 2024 | -$1.12 | -$0.96 | -$1.06 - -$0.79 | -16.12% | Miss | N/A | 11 | 3 up, 0 down | Feb 26, 2025 | $261.59M |
| Sep 30, 2024 | -$0.94 | -$0.88 | -$0.97 - -$0.77 | -6.82% | Miss | N/A | 15 | 0 up, 1 down | Nov 6, 2024 | N/A |
| Jun 30, 2024 | -$0.81 | -$0.76 | -$0.84 - -$0.70 | -6.58% | Miss | N/A | 15 | 1 up, 0 down | Aug 7, 2024 | N/A |
| Mar 31, 2024 | -$0.70 | -$0.72 | -$0.85 - -$0.67 | +2.78% | Beat | N/A | 11 | 0 up, 0 down | May 8, 2024 | N/A |
| Dec 31, 2023 | -$1.14 | -$0.88 | -$1.10 - -$0.70 | -29.55% | Miss | N/A | 11 | 1 up, 0 down | Feb 26, 2024 | $742000 |
| Sep 30, 2023 | -$0.99 | -$1.00 | -$1.05 - -$0.94 | +1.00% | Beat | N/A | 8 | 0 up, 0 down | Nov 6, 2023 | N/A |
| Jun 30, 2023 | -$0.92 | -$0.82 | -$0.88 - -$0.77 | -12.20% | Miss | N/A | 8 | 0 up, 1 down | Aug 8, 2023 | $3.82M |
| Mar 31, 2023 | -$0.72 | -$0.80 | -$0.92 - -$0.69 | +10.00% | Beat | N/A | 8 | 2 up, 0 down | May 8, 2023 | $7.01M |
| Dec 31, 2022 | -$0.63 | -$0.82 | -$0.90 - -$0.68 | +23.17% | Beat | N/A | 10 | 0 up, 0 down | Feb 27, 2023 | $13.79M |
| Sep 30, 2022 | -$0.87 | -$0.85 | -$1.02 - -$0.71 | -2.35% | Miss | N/A | 9 | 0 up, 0 down | Nov 7, 2022 | $3.36M |
| Jun 30, 2022 | -$0.82 | -$0.84 | N/A | +2.38% | Beat | N/A | N/A | 0 up, 0 down | Aug 9, 2022 | $9.12M |
| Mar 31, 2022 | -$0.78 | -$0.77 | -$0.88 - -$0.68 | -1.30% | Miss | N/A | 6 | 0 up, 0 down | May 9, 2022 | $7.58M |
| Dec 31, 2021 | -$0.71 | -$0.64 | -$0.72 - -$0.55 | -10.94% | Miss | N/A | 7 | N/A | Feb 28, 2022 | $9.46M |
| Sep 30, 2021 | -$0.72 | -$0.62 | -$0.66 - -$0.57 | -16.13% | Miss | N/A | 6 | 1 up, 0 down | Nov 10, 2021 | $1.10M |
| Jun 30, 2021 | -$0.60 | -$0.56 | -$0.60 - -$0.51 | -7.14% | Miss | N/A | 6 | N/A | Aug 11, 2021 | $8.70M |
| Mar 31, 2021 | -$0.53 | -$0.52 | -$0.56 - -$0.46 | -1.92% | Miss | N/A | 5 | N/A | May 10, 2021 | $10.13M |
| Dec 31, 2020 | -$0.52 | -$0.38 | -$0.45 - -$0.22 | -36.84% | Miss | N/A | 5 | N/A | Mar 2, 2021 | $8.75M |
| Sep 30, 2020 | -$0.42 | -$0.40 | -$0.44 - -$0.34 | -5.00% | Miss | N/A | 5 | N/A | Nov 12, 2020 | $12.66M |
| Jun 30, 2020 | -$0.46 | -$0.37 | -$0.40 - -$0.33 | -24.32% | Miss | N/A | 5 | N/A | Aug 10, 2020 | $10.03M |
| Mar 31, 2020 | -$0.74 | -$0.36 | -$0.41 - -$0.28 | -105.56% | Miss | N/A | 4 | N/A | May 14, 2020 | $11.55M |
| Dec 31, 2019 | -$6.52 | -$0.41 | -$0.62 - -$0.26 | N/A | N/A | N/A | 3 | N/A | Feb 13, 2020 | $12.09M |
| Sep 30, 2019 | -$0.37 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 27, 2019 | $12.51M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$5.91, after -$3.57 the year before. It was -$6.89 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$5.91 | N/A |
| Dec 31, 2024 | -$3.57 | N/A |
| Dec 31, 2023 | -$3.77 | N/A |
| Dec 31, 2022 | -$3.10 | N/A |
| Dec 31, 2021 | -$2.56 | N/A |
| Dec 31, 2020 | -$2.14 | N/A |
| Dec 31, 2019 | -$6.89 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,600 words across 21 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,639 | 21 | |
| 2026Q2 | Jun 30, 2026 | 7,540 | 18 | |
| 2026Q1 | Mar 31, 2026 | 5,417 | 22 | |
| 2025Q4 | Dec 31, 2025 | 7,209 | 22 | |
| 2025Q3 | Sep 30, 2025 | 7,196 | 22 | |
| 2025Q2 | Jun 30, 2025 | 6,396 | 17 | |
| 2025Q1 | Mar 31, 2025 | 7,454 | 12 | |
| 2024Q4 | Dec 31, 2024 | 8,565 | 16 |
2026Q3 Earnings Call
Opening remarks
Ryan Asay Senior Vice President, Corporate Affairs Thank you, and welcome, everyone, to the Third Quarter 2026 Earnings Call. Joining me on today's call are Dr. Mark A. Goldsmith, Revolution Medicines' Chairman and Chief Executive Officer; Anthony Mancini, our Chief Global Commercialization Officer; Dr. Alan Bart Sandler, our Chief Development Officer; and Jack Anders, our Chief Financial Officer. Dr. Wei Lin, our Chief Medical Officer, will join us for the Q&A portion of today's call. I would like to inform you that certain statements we make during this call will be forward-looking. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our recent periodic report filed with the U.S. Securities and Exchange Commission. This afternoon, we released financial results for the quarter ended September 30, 2026, and recent corporate updates. The press release and updated corporate presentation are available on the Investors section of our website at revmed.com. With that, I will turn the call over to our Chief Executive Officer, Dr. Mark A. Goldsmith. Mark?
Mark A. Goldsmith Chairman and Chief Executive Officer Thank you, Ryan, and good afternoon, everyone. I will begin today with several remarks focused on our progress in pancreatic cancer and across our broader RAS(ON) portfolio. Anthony will then provide an update on the initial launch of RAS(ON)Q. Alan will discuss progress across our clinical development programs, and Jack will review our third-quarter financial results before I return with brief concluding remarks. The third quarter marked a transformational period for Revolution Medicines. On August 26, less than two years after enrollment began in the global randomized RASolute 302 clinical trial, the FDA approved RAS(ON)Q for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic therapy. We immediately began making it available by prescription in the United States. The approval provided an important regulatory proof point for our RAS(ON) approach and marked the beginning of a new chapter for our company. More importantly, eligible patients and their physicians now have an approved oral targeted medicine designed to directly and broadly inhibit RAS, the main cause of pancreatic cancer, in a disease with a profound need for therapeutic breakthroughs. This milestone reflects years of scientific conviction, disciplined development, and focused execution by our team and collaborators. It also formally opens the delivery phase of responsibility for Revolution Medicines. We are working tirelessly to execute the U.S. launch with urgency, help eligible patients access daraxonrasib promptly, support a positive treatment experience, and rigorously prepare to expand the launch internationally. With the U.S.
Frequently Asked Questions About RVMD
When is Revolution Medicines's next earnings date?
Revolution Medicines's next earnings report is expected for Feb 23, 2027.
Did RVMD beat earnings estimates last quarter?
Yes. Revolution Medicines reported EPS of -$1.90 for the quarter ended Sep 30, 2026, above the -$2.34 estimate, a 18.80% surprise.
What EPS do analysts expect from RVMD next quarter?
The consensus EPS estimate for Revolution Medicines for the quarter ending Dec 31, 2026 is -$1.87 from 25 analysts, with estimates from -$3.46 to -$0.85.
How often does RVMD beat earnings estimates?
Revolution Medicines beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -12.52%.
RVMD pages: Overview, Earnings, Forecast, Financials, Competitors